Latest Avoro Capital Advisors LLC Stock Portfolio
Avoro Capital Advisors LLC Performance:
2024 Q3: -0.02%YTD: 7.82%2023: 0.12%
Performance for 2024 Q3 is -0.02%, and YTD is 7.82%, and 2023 is 0.12%.
About Avoro Capital Advisors LLC and 13F Hedge Fund Stock Holdings
Avoro Capital Advisors LLC is a hedge fund based in NEW YORK, NY. On 10-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $7.8 Billions. In it's latest 13F Holdings report, Avoro Capital Advisors LLC reported an equity portfolio of $6.9 Billions as of 30 Sep, 2024.
The top stock holdings of Avoro Capital Advisors LLC are UTHR, , . The fund has invested 14.9% of it's portfolio in UNITED THERAPEUTICS CORP and 10.9% of portfolio in ASCENDIS PHARMA.
The fund managers got completely rid off CEREVEL THERAPEUTICS HLDNG (CERE), SPDR SERIES TRUST - S&P BIOTECH (BIL) and ALNYLAM PHARMCEUTICALS INC. (ALNY) stocks. They significantly reduced their stock positions in SPYRE THERAPEUTICS INC (AGLE), IOVANCE BIOTHERAPEUTICS INC (IOVA) and BIOMARIN PHARMACEUTICAL INC (BMRN). The fund showed a lot of confidence in some stocks as they added substantially to DYNE THERAPEUTICS INC. (DYN), VAXCYTE INC (PCVX) and MONTE ROSA THERAPEUTICS INC (GLUE).
The top stock holdings of Avoro Capital Advisors LLC are UTHR, , . The fund has invested 14.9% of it's portfolio in UNITED THERAPEUTICS CORP and 10.9% of portfolio in ASCENDIS PHARMA.
The fund managers got completely rid off CEREVEL THERAPEUTICS HLDNG (CERE), SPDR SERIES TRUST - S&P BIOTECH (BIL) and ALNYLAM PHARMCEUTICALS INC. (ALNY) stocks. They significantly reduced their stock positions in SPYRE THERAPEUTICS INC (AGLE), IOVANCE BIOTHERAPEUTICS INC (IOVA) and BIOMARIN PHARMACEUTICAL INC (BMRN). The fund showed a lot of confidence in some stocks as they added substantially to DYNE THERAPEUTICS INC. (DYN), VAXCYTE INC (PCVX) and MONTE ROSA THERAPEUTICS INC (GLUE).
Avoro Capital Advisors LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Avoro Capital Advisors LLC made a return of -0.02% in the last quarter. In trailing 12 months, it's portfolio return was 23.38%.
New Buys
Additions
| Ticker | % Inc. |
|---|---|
| dyne therapeutics inc. | 461 |
| vaxcyte inc | 104 |
| monte rosa therapeutics inc | 27.68 |
| ascendis pharma | 18.88 |
| kymera therapeutics inc | 15.71 |
| krystal biotech inc | 7.78 |
| avidity biosciences inc | 5.69 |
| soleno therapeutics inc | 4.27 |
Additions to existing portfolio by Avoro Capital Advisors LLC
Reductions
| Ticker | % Reduced |
|---|---|
| spyre therapeutics inc | -67.45 |
| iovance biotherapeutics inc | -63.76 |
| biomarin pharmaceutical inc | -55.28 |
| amicus therapeutics inc. | -15.42 |
| sarepta therapeutics inc | -14.81 |
| biocryst pharmaceuticals inc | -5.61 |
| madrigal pharmaceuticals inc | -1.29 |
| mannkind corp | -0.11 |
Avoro Capital Advisors LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| cerevel therapeutics hldng | -308,292,000 |
| verrica pharmaceuticals inc | -29,160,000 |
| spdr series trust - s&p biotech | -281,375,000 |
| bicycle therapeutics plc | -14,168,000 |
| adverum biotechnologies inc | -2,858,330 |
| alnylam pharmceuticals inc. | -97,200,000 |
Avoro Capital Advisors LLC got rid off the above stocks
Sector Distribution
Avoro Capital Advisors LLC has about 78.1% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 78.1 |
| Others | 21.9 |
Market Cap. Distribution
Avoro Capital Advisors LLC has about 21.7% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 47.6 |
| UNALLOCATED | 22.5 |
| LARGE-CAP | 21.7 |
| SMALL-CAP | 7.6 |
Stocks belong to which Index?
About 41.8% of the stocks held by Avoro Capital Advisors LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 58.2 |
| RUSSELL 2000 | 41.8 |
Avoro Capital Advisors LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Avoro Capital Advisors LLC
Avoro Capital Advisors LLC has 35 stocks in it's portfolio. About 69.6% of the portfolio is in top 10 stocks. MDGL proved to be the most loss making stock for the portfolio. UTHR was the most profitable stock for Avoro Capital Advisors LLC last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AADI | aadi biosciences inc | 0.09 | 2,849,400 | 5,869,770 | unchanged | 0.00 | ||
| ADVM | adverum biotechnologies inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AGLE | spyre therapeutics inc | 0.26 | 598,600 | 17,604,800 | reduced | -67.45 | ||
| ALNY | alnylam pharmceuticals inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| APLS | apellis pharmaceuticals inc. | 4.67 | 11,111,100 | 320,444,000 | unchanged | 0.00 | ||
| ARWR | arrowhead pharmaceuticals inc. | 2.51 | 8,888,890 | 172,178,000 | unchanged | 0.00 | ||
| AUTL | autolus therapeutics plc | 0.65 | 12,345,700 | 44,814,800 | unchanged | 0.00 | ||
| BCRX | biocryst pharmaceuticals inc | 1.31 | 11,865,000 | 90,174,000 | reduced | -5.61 | ||
| BCYC | bicycle therapeutics plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BIL | spdr series trust - s&p biotech | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BMRN | biomarin pharmaceutical inc | 2.09 | 2,038,020 | 143,252,000 | reduced | -55.28 | ||
| CERE | cerevel therapeutics hldng | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| DYN | dyne therapeutics inc. | 0.34 | 650,000 | 23,348,000 | added | 461 | ||
| FOLD | amicus therapeutics inc. | 3.61 | 23,175,000 | 247,509,000 | reduced | -15.42 | ||
| GLUE | monte rosa therapeutics inc | 0.45 | 5,790,240 | 30,688,300 | added | 27.68 | ||
| IOVA | iovance biotherapeutics inc | 0.58 | 4,240,000 | 39,813,600 | reduced | -63.76 | ||
| ITCI | intra-cellular therapies inc | 3.25 | 3,050,000 | 223,168,000 | added | 1.67 | ||
| KRYS | krystal biotech inc | 6.96 | 2,622,220 | 477,323,000 | added | 7.78 | ||
| KURA | kura oncology inc | 1.01 | 3,541,500 | 69,201,000 | unchanged | 0.00 | ||
| KYMR | kymera therapeutics inc | 3.11 | 4,500,000 | 212,985,000 | added | 15.71 | ||